The 2025 J.P. Morgan Healthcare Conference ignited a new era of M&A activity, marking the industry’s largest consolidation wave in recent years.
The M&A rebound in the healthcare sector has been years in the making, as pharma giants like J&J, GSK, and others face looming patent cliffs, threatening billions in revenue. Companies are under increasing pressure to refill their pipelines. This urgency has sparked a surge in both early and late-stage asset acquisitions. In the coming year, we can expect continued momentum in deal-making, with larger financing sizes linked to milestone-based acquisitions that help mitigate development risks.
At the fo...
